<DOC>
	<DOCNO>NCT02211144</DOCNO>
	<brief_summary>Study assess safety pharmacokinetics BIRB 796 BS tablet administer multiple daily dose various dose level</brief_summary>
	<brief_title>Safety Pharmacokinetics BIRB 796 BS Tablets Administered Twice Daily Orally Healthy Human Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male female subject determine result screen Signed write informed consent accordance Good Clinical Practice ( GCP ) local legislation Female subject lactate child bear potential define surgically sterile post menopausal ( period least 12 month elevate follicle stimulate hormone ( FSH ) low estradiol estrogen supplementation ) . Females use barrier contraception ( e.g . condom ) prior administration study medication , study least one month release study . Women must negative blood pregnancy test Age ≥ 18 ≤ 60 year Body mass index ( BMI ) ≥ 18.5 ≤ 29.9 kg/m2 Able communicate well investigator comply study requirement Laboratory value within clinically define reference range Any finding medical examination ( include blood pressure , pulse rate , electrocardiogram ) deviate normal clinical relevance Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunologic hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator History vasculitis ( past history fever , malaise , myalgia , rash , etc . ) Intake drug long halflife ( &gt; 24 hour ) ( &lt; 1 month prior administration trial ) Use drug , might influence result trial , ( &lt; 10 day prior administration trial ) Participation another trial investigational drug ( &lt; 1 month prior administration ( least 10 time relevant elimination halflife ) trial ) Having prescription medication 2 week prior study drug administration counter medication 1 week prior study drug administration ( least 10 time relevant elimination halflife ) Smoker Alcohol abuse ( &gt; 60 g/day ) Drug abuse Use methylxanthinecontaining drink food ( coffee , tea , cola , energy drink , chocolate , etc . ) , grapefruit grapefruit juice , alcohol , green tea , tobacco &lt; 5 day prior administration study drug Blood donation loss &gt; 400 mL ( &lt; 1 month prior administration trial ) Excessive physical activity ( &lt; 5 day prior administration trial ) Following specific laboratory finding : white blood cell count , Creactive protein , gammaglutamyltransferase , aspartate transaminase , alanine transaminase , glutamate dehydrogenase normal range ; erythrocytes &gt; 15 mg/dl protein urine dipstick menstruate Any EKG value outside reference range clinical relevance include , limited QTcB &gt; 480 m QRS interval &gt; 110 ms History familial bleeding disorder Inability comply dietary regimen study centre Inability comply investigator 's instruction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>